Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®

Core Viewpoint - Microbot Medical Inc. has appointed Ms. Michal Ahuvia as the Director of Operations to enhance production efficiency and prepare for the commercial launch of the LIBERTY® Endovascular Robotic System, expected in Q2 2025 [1][3]. Group 1: Appointment and Role - Ms. Michal Ahuvia has over 20 years of experience in operations, focusing on process transformation, performance improvement, and supply chain management [2]. - In her new role, Ms. Ahuvia will be responsible for ramping up production and improving efficiencies as the company prepares for the LIBERTY® launch [1][3]. Group 2: Company Background - Microbot Medical Inc. is a pre-commercial stage medical technology company aiming to enhance patient care globally with its innovative single-use, fully disposable endovascular robotic system [3]. - The LIBERTY® system is designed to overcome traditional barriers to accessing advanced robotic systems in medical procedures [3]. Group 3: Leadership Perspective - Harel Gadot, Chairman and CEO, emphasized the importance of efficient production ramp-up as a critical part of the company's commercial strategy and future success [3]. - He expressed confidence in Ms. Ahuvia's ability to execute operational plans and meet commercial objectives [3].